HILDEN, Germany and GERMANTOWN, Maryland, March 30, 2017 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has joined CANCER-ID, a public-private consortium aiming to establish standard protocols and clinical validation for blood-based biomarkers in lung and breast cancer.
Rapid advances in the use of liquid biopsies, which enable cancer treatment and monitoring through the identification of circulating tumor cells and tumor-related nucleic acids in blood samples, have highlighted the need for standardized methods and workflows to avoid unreliable or even false analytical test results, including sequencing bias. The CANCER-ID consortium of 36 partners from 13 countries is a project of Europe's Innovative Medicines Initiative (IMI) and will conduct clinical trials using liquid biopsy methods as part of its efforts to accelerate the development of better and safer medicines for patients.
"QIAGEN is pleased to be joining CANCER-ID to help develop standards and conduct clinical validation to enable broad adoption of reliable molecular analyses from liquid biopsies. Personalized healthcare is providing life-saving genomic insights, and blood-based biomarkers offer the potential to transform diagnosis and patient monitoring due to significantly easier access," said Markus Sprenger-Haussels, Senior Director and Head of Sample Technologies in the Life Sciences Business Area.
Click here for the full press release
SOURCE QIAGEN N.V.